Lowering Drug Prices with the Anti-Kickback Statute: Future and Impact of HHS Final Rule to Disrupt Drug Formulary Rebates
This Briefing is brought to you by AHLA’s Payers, Plans, and Managed Care Practice Group.
- December 22, 2020
- Alan J. Arville , Epstein Becker & Green PC
- Alexis Boaz, JD, MPH , Epstein Becker & Green PC
2019 may seem like ages ago, but before COVID-19, a top, if not the top, health policy priority of the Trump administration (administration) was to address rising prescription drug costs. A key policy initiative championed by Alex Azar, Secretary of the Department of Health and Human Services (HHS), to curb drug prices was to eliminate the current structure of formulary rebates paid by drug manufacturers to pharmacy benefit managers (PBMs) and health plans. To this end, on January 31, 2019, the HHS Office of Inspector General (OIG) issued the proposed rule to restrict safe harbor protection for formulary rebates under the Anti-Kickback Statute (Proposed Rule).
You must be logged in to access this content.